Introduction
Ticlopidine, a potent antiplatelet agent, is widely used for the treatment of cerebrovascular disease 1)2) and coronary artery disease.
3) The combination of aspirin and ticlopidine is recently considered a standard regimen for the prevention of subacute stent thrombosis after coronary stent implantation. 4)5) Neutropenia is the most worrisome adverse reaction to this agent, occuring in 1-2% of patients. 1)2)6) Reversible abnormal liver function tests were reported in only 1% of patients receiving the drug in two large clinical trials. 1)2) Severe cholestasis has rarely been reported, with approximately 12 case reports including only five from the English medical literatures. [7] [8] [9] [10] [11] We report the first case of severe cholestasis and subsequent pancytopenia associated with use of ticlopidine after coronary stent implantation.
Case Report
A 54-year-old male was transferred for painless jaundice of one week duration. There was no history of blood transfusion, jaundice, significant alcohol ingestion, hepatitis or gallstone disease. He had a previous history of unstable angina 1 month ago and underwent coronary stent implantation for critical stenosis of the proximal left anterior descending artery 15 days ago. Thereafter, he began to take aspirin 100 mg qd , ticlopidine 250 mg bid , isosorbide dinitrate 40 mg bid , and atenolol 25 mg bid . On clinical examination, he was deeply jaundiced and maculopapular rash was present on the whole body. His blood pressure and pulse rate were 110/70 mmHg and 80 beats per minute respectively. No other stigmata of chronic liver disease was present.
His abdomen was soft, not tender and both liver and spleen were not palpable.
Investigations
Initial laboratory findings were as follows hemoglobin level 8.1g/dl, total white cell count 6. 8 Abdominal ultrasound and CT scan revealed a normal sized liver without any focal lesions. The intra and extrahepatic biliary ducts were not dilated and no gallstones were detected. Endoscopic retrograde cholangiopancreatography showed no abnormalities. All medications including ticlopidine were discontinued and supportive therapy including hepatotonic agents was done. A percutaneous liver biopsy was not carried out because his liver function tests were progressively deteriorated than 10 ug/ml 2-8 . Platelets transfusion was ineffective. Prednisolone of 30 mg/day was tried and it was effective to raise the blood components. His blood components and liver function tests were slowly resolved and he was discharged at 113 days after coronary stent implantation. At the 17 days after discharge, his blood cells and liver function tests were much recovered and he felt better.
Discussion
Ticlopidine is an antiplatelet agent used worldwide for a variety of vascular disorders in which platelets play a prominent role. 12) Studies in animals and human demonstrated that ticlopidine is a potent inhibitor of platelet aggregation induced by adenosine diphosphate ADP , and variably inhibits aggregation by collagen, epinephrine, arachidonic acid, thrombin, and platelet activating factor. Its action is both dose-and time-related, with its onset of activity being 24 to 48 hours, its maximal activity occuring after 3 to 5 days, and its activity still being present 72 hours after a final dose. Overall, side effects occur in 10 to 15% of patients receiving ticlopidine. The most common side effects are gastrointestinal disturbances and skin rashes, neither of which necessarily require discontinuation of therapy in most patients. Neutropenia is the most worrisome and occurs in 1 2% of patients. 1)2) As a result, complete blood counts with white cell differentials is recommended every 2 weeks during the first 3 months of therapy.
Reversible abnormal liver function tests were reported in only 1% of patients receiving the drug in two large clinical trials. Alkaline phosphatase and transaminase were elevated and varied widely. Jaundice resolved over a period of 10 days to 3 months after drug withdrawal. The time taken for liver function to normalize after discontinuation of the drug ranged from 5 days to 8 months. 7) Biopsies performed in four cases and demonstrated cholestasis. Centrilobular acidophilic necrosis and a portal lymphoplasmacytic infiltrate were seen in one case, 13) and spotty moderate necrosis in another. 14) Rechallenge has not been reported. 15) and thrombocytopenia 12) were reported to be associated with the use of ticlopidine.
Cholestatic jaundice due to ticlopidine is a rare idiosyncratic side effect that resolves predictably with drug withdrawal without apparent sequelae. Adverse hepatic effects usually occur within the first 3 months of therapy. Patients should be informed to see a physician if they experience weakness, nausea, emesis, decreased appetite, weight loss, painless jaundice or icteric sclera, elevated liver enzyme. The clinician should be aware of this potentially reversible condition and undertake careful history taking, physical examinations, complete blood counts and liver function tests as well as white blood cell count, particularly because a favorable response to drug withdrawal may obviate the need for extensive investigations. The safety and efficacy of 2 weeks of ticlopidine therapy 16) or new antiplatelet agents such as cilostazol and clopidogrel 17)18) are now reported after coronary stent implantation.
